Zyn Lawsuit 2026: The Full Legal Picture Behind The Nicotine Pouch Controversy

Yes, for those still asking, there is a Zyn lawsuit. Actually, there are several. Most coverage online treats “the Zyn lawsuit” as one case. It isn’t.

Rather, it’s a cluster of separate legal actions running in different courts, filed by different plaintiffs, over different alleged harms.

I want to walk through what each case claims, where it stands, and one detail almost no other coverage mentions: an FDA ruling that sits in real tension with the core allegation driving most of this litigation.

What The Zyn Lawsuits Actually Allege

Nearly every case traces back to one core claim.

Plaintiffs say Philip Morris International and its subsidiary, Swedish Match North America, marketed Zyn as “tobacco-free.” But the nicotine inside the pouches comes from tobacco, not a synthetic source, they argue.

That distinction matters legally. “Tobacco-free” implies a category of risk reduction the product may not actually deliver.

A 2024 class action filed in California laid this claim out in detail. The complaint cites lab studies that found formaldehyde, ammonia, nickel, and chromium in Zyn pouches.

It also cites tobacco-specific nitrosamines linked to cancer, according to ClassAction.org’s reporting on the filing. So the suit argues: if these compounds trace back to tobacco, calling the product “tobacco-free” is flatly false, not just misleading.

A separate strand of litigation goes further. It alleges the marketing itself was built to attract teenagers, using flavors like mint, citrus, and cinnamon.

The Youth-Marketing Claims

Several plaintiffs argue Philip Morris ran the same playbook the tobacco industry used for cigarettes decades ago.

One 2024 complaint put it bluntly.

The companies “pulled out every play in the tobacco-industry playbook,” per ClassAction.org’s summary of the filing. They leaned on social-media promotion and candy-adjacent flavors, the complaint says, to build a new generation of nicotine users.

Baltimore took this argument to city court directly. In May 2025, the city sued Philip Morris and Swedish Match under its Consumer Protection Ordinance.

The suit cites survey data showing nearly 2% of middle and high school students report using nicotine pouches.

It also notes that more than two-thirds of underage users name Zyn as their favorite brand, according to the city’s press release. Mayor Brandon Scott called the marketing practices exploitative.

The Legal Age Gap Behind the Youth-Marketing Claims 

Federal law sets the minimum age to buy tobacco and nicotine products, including Zyn, at 21. Congress raised it from 18 in December 2019, per the FDA’s Tobacco 21 notice and the amendment to Section 906(d) of the Federal Food, Drug, and Cosmetic Act, specifically to curb youth nicotine use.

That age floor matters here.

Plaintiffs like Friedman allege they became addicted to Zyn as teenagers – years before they could legally buy it. Their claim isn’t just that the marketing was misleading. It’s that it worked on an audience the law says shouldn’t have had access at all.

That gap, between a 21-year legal purchase age and marketing plaintiffs say targeted teens, is part of what makes the youth-marketing allegations legally distinct from an ordinary false-advertising claim. 

Where The Individual Litigation Stands

Beyond the class actions, a smaller set of individual plaintiffs allege Zyn caused them direct, personal harm – specifically, nicotine addiction that started in their teenage years.

The most advanced of these is Friedman v. Philip Morris International, filed in April 2025 in the Southern District of Florida. Alannah Friedman alleges the companies defectively designed Zyn.

She also says they failed to warn her about its risks and marketed it toward minors, according to Philip Morris International’s own SEC disclosures.

Her case has since been consolidated with three related Florida suits – Kelly, Palmer, and Lendinara – for shared pretrial discovery.

That consolidated litigation has a real trial date: December 7, 2026, per Philip Morris’s most recent quarterly filing.

A federal judge already narrowed the case once. The judge dismissed a fraud claim for lacking specific detail, but let the core allegations move forward – design defect, failure to warn, and negligence – per Tobacco Reporter’s April 2025 coverage.

Separately, a Miami federal judge issued a further ruling in December 2025. That ruling allowed a deceptive-trade-practices claim under Florida law to proceed, even after the plaintiff’s fraud claim had already been dismissed twice, according to Law.com. 

This distinction matters: Florida’s deceptive-trade-practices statute doesn’t require proving intent to deceive, unlike a fraud claim. So it gives plaintiffs a lower bar to clear.

Regulatory And Government Actions

Not every case comes from a private plaintiff. Government agencies have brought their own actions, and one has already resulted in a payout.

In December 2024, DC’s Attorney General announced that Swedish Match would pay $1.2 million. The payment settles allegations it violated the district’s 2022 flavored tobacco ban.

The investigation found the company sold flavored Zyn products through its website to DC customers between October 2022 and June 2024, according to the AG’s office.

As part of the deal, Swedish Match agreed to monitor its distributors and stop selling flavored products in DC online going forward.

Still, that settlement resolves one city’s specific consumer-protection claim. It doesn’t touch any broader question about Zyn’s safety or advertising nationwide.

The Case That Didn’t Survive

Not every legal challenge has succeeded. In September 2025, a federal judge in Virginia dismissed a proposed antitrust class action accusing Philip Morris of using its 2022 acquisition of Swedish Match to inflate Zyn prices.

Judge David Novak ruled the plaintiffs failed to show the deal actually harmed competition, and he dismissed the case with prejudice, according to Reuters.

Swedish Match’s market share stayed essentially unchanged after the acquisition, the judge noted – a detail that undercut the monopoly theory driving the suit.

So not every legal theory against Zyn is holding up in court. The pricing claims failed. The tobacco-free and youth-marketing claims, so far, have not.

The FDA Paradox Nobody’s Talking About

Here’s the detail I think matters most.

On June 30, 2026, the FDA authorized 20 specific Zyn products to carry a modified-risk marketing claim.

Under this authorization, Swedish Match can now legally advertise that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” That’s per the FDA’s own announcement, issued after what it called an extensive scientific review.

This creates a genuine tension with the litigation running in parallel. The lawsuits argue Zyn’s marketing misleads consumers about health risk. Yet the FDA, at the same time, now permits Zyn to make an explicit health-risk comparison to cigarettes.

The two aren’t necessarily contradictory.

A product can be lower-risk than cigarettes while still being addictive, and while its “tobacco-free” label remains disputed. But coverage of this litigation rarely acknowledges both facts exist at once.

Public health researchers have pushed back directly. Aaron Hunt of Utah State University told PBS News that the FDA’s decision “doesn’t change the fact that these products deliver an addictive dose of nicotine.”

What This Means If You’ve Used Zyn

If you’re a current or former Zyn user trying to figure out where you stand, here’s the practical picture.

The class actions target consumers broadly, based on the “tobacco-free” labeling claim. They don’t require proof of a specific injury to potentially qualify.

The individual addiction cases work differently, though. Those plaintiffs allege direct personal harm, typically starting nicotine use as a minor, and they pursue individual damages rather than class-wide relief.

So, if you started using Zyn as a teenager and believe the marketing influenced that decision, an attorney familiar with tobacco litigation can evaluate whether your case fits the Friedman-Kelly-Palmer pattern.

But if you’re simply a purchaser who feels misled by “tobacco-free” claims, the broader consumer class actions are the more relevant track. That’s because a certified class could eventually cover any qualifying buyer without a separate filing.

Zyn’s Legal Status Outside the U.S.

Zyn is a U.S.-market product, and none of this litigation applies outside American courts. Still, the underlying regulatory questions have real echoes elsewhere.

The UK and most EU states permit nicotine pouch sales. But they regulate nicotine strength and advertising more tightly than current U.S. law does.

India takes a stricter position. The Prohibition of Electronic Cigarettes Act of 2019 bars the manufacture, sale, and advertisement of electronic nicotine delivery systems, and regulators generally treat oral nicotine pouches under similar restrictions. So Zyn isn’t legally sold there.

For people outside the U.S., the transferable lesson isn’t the American lawsuits themselves. It’s the regulatory question every jurisdiction faces: how to classify and warn about products that deliver nicotine without tobacco leaf.

A Few Direct Questions Worth Answering

Here are a few questions that crossed my mind while researching on this Zyn lawsuit:

Is Zyn Actually Tobacco-Free?

Not entirely. The pouches don’t contain tobacco leaf, but the nicotine itself is derived from tobacco plants, not synthesized, according to lab studies cited in the 2024 California complaint.

Has Any Court Ruled Zyn’s Marketing Illegal?

Not yet. Courts have allowed several claims to proceed past dismissal, meaning judges found the allegations plausible enough to litigate – different from a final ruling on the merits.

Can I Join One Of These Lawsuits?

Depends on the case. Class actions generally don’t require you to file anything personally until a class is certified and, if applicable, a settlement fund opens. Individual addiction claims require retaining your own attorney.

Does The FDA’s Approval Undercut The Lawsuits?

Not automatically. The FDA’s authorization addresses comparative risk to cigarettes. It doesn’t resolve the separate legal question of whether “tobacco-free” labeling misled consumers – different claims, different standards.

Sources:

• ClassAction.org on the 2024 California false-advertising complaint
• The City of Baltimore and DiCello Levitt on the Consumer Protection Ordinance suit
• Philip Morris International’s SEC filings on consolidated Florida litigation and trial scheduling
• Tobacco Reporter on the March 2025 partial dismissal
• Law.com’s Daily Business Review on the December 2025 Miami ruling
• the DC Attorney General’s December 2024 settlement announcement
• Reuters on the September 2025 antitrust dismissal
• The FDA’s June 2026 modified risk authorization
• PBS News on public health reaction
• India’s Prohibition of Electronic Cigarettes Act, 2019.

Read Also:

• Mr. Cooper Class Action Lawsuit: What We Should Know About Unlawful Home Loan Services
• Smoothstack Lawsuit: Beware of Unlawful Wage Scheme and Employment Contracts
• Kennedy Funding Lawsuit and the Exploitation of Arkansas Statute of Frauds